| scholarly article | Q13442814 |
| P356 | DOI | 10.1034/J.1600-6143.2002.20907.X |
| P8608 | Fatcat ID | release_cvlf6t6nuje4notvcmarjf6l4i |
| P698 | PubMed publication ID | 12392291 |
| P5875 | ResearchGate publication ID | 11070792 |
| P2093 | author name string | Anders Hartmann | |
| Torbjørn Leivestad | |||
| Aksel Foss | |||
| Per Fauchald | |||
| Kåre Osnes | |||
| Halvor Rollag | |||
| Solbjørg Sagedal | |||
| Helge Scott | |||
| Miklos Degré | |||
| Knut P Nordal | |||
| Ståle Sund | |||
| P2860 | cites work | International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology | Q34354852 |
| Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses | Q40609987 | ||
| Increased impact of acute rejection on chronic allograft failure in recent era. | Q43774694 | ||
| Late-acute renal allograft rejection and symptomless cytomegalovirus infection | Q43831019 | ||
| Cytomegalovirus infection-enhanced chronic kidney allograft rejection is linked with intercellular adhesion molecule-1 expression | Q44676762 | ||
| Diagnosis of cytomegalovirus infection in kidney transplant recipients by a quantitative RNA-DNA hybrid capture assay for cytomegalovirus DNA in leukocytes | Q47964998 | ||
| Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. | Q53346269 | ||
| The Banff 97 working classification of renal allograft pathology | Q59314413 | ||
| Effect of recipient sensitization (peak PRA) on graft outcome in haploidentical living related kidney transplants | Q60998184 | ||
| The impact of an acute rejection episode on long-term renal allograft survival (t1/2) | Q72354298 | ||
| Cytomegalovirus infection--an etiological factor for rejection? A prospective study in 242 renal transplant patients | Q72965751 | ||
| A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients | Q73152669 | ||
| Renal allograft dysfunction associated with cytomegalovirus infection | Q73181330 | ||
| Critical evaluation of the association of acute with chronic graft rejection in kidney and heart transplant recipients. The Collaborative Transplant Study | Q73278465 | ||
| A strong impact of matching for a limited number of HLA-DR antigens on graft survival and rejection episodes: a single-center study of first cadaveric kidneys to nonsensitized recipients | Q77291269 | ||
| The clinical significance of cytomegaloviral inclusions in the allograft kidney | Q77916208 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Cytomegalovirus | Q6946 |
| cytomegaloviral disease | Q2076966 | ||
| P304 | page(s) | 850-856 | |
| P577 | publication date | 2002-10-01 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients | |
| P478 | volume | 2 |
| Q38041260 | A drug safety evaluation of everolimus in kidney transplantation |
| Q46742552 | A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients. |
| Q79368688 | Acute cytomegalovirus infection complicated by venous thrombosis in a renal transplant recipient |
| Q37965695 | Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy |
| Q37411026 | Allograft rejection-related gene expression in the endothelial cells of renal transplantation recipients after cytomegalovirus infection |
| Q38723077 | Alloimmunity But Not Viral Immunity Promotes Allograft Loss in a Mouse Model of Polyomavirus-Associated Allograft Injury. |
| Q30438204 | Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation |
| Q35124583 | Blood dendritic cell levels associated with impaired IL-12 production and T-cell deficiency in patients with kidney disease: implications for post-transplant viral infections. |
| Q43583466 | CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages. |
| Q28073770 | CMV-Specific CD8 T Cell Differentiation and Localization: Implications for Adoptive Therapies |
| Q36884566 | Can mTOR inhibitors reduce the risk of late kidney allograft failure? |
| Q48423173 | Change of peripheral blood mononuclear cells IFN-gamma, IL-10, and TGF-beta1 mRNA expression levels with active human cytomegalovirus infection in orthotopic liver transplantation |
| Q37318303 | Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients |
| Q39502888 | Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience |
| Q46692833 | Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience |
| Q54624695 | Comparison of quantitative PCR and antigenemia in cytomegalovirus infection in renal transplant recipients. |
| Q46690554 | Concentration-controlled use of sirolimus associated with reduced exposure of cyclosporine in black recipients of primarily living renal allograft donors: 12-month results. |
| Q57515316 | Cost analysis in favor of a combined approach for cytomegalovirus after kidney transplantation: a single-center experience |
| Q90705285 | Cytomegalovirus Disease After Liver Transplant-A Description of a Treatment-Resistant Case: A Case Report and Literature Review |
| Q97092937 | Cytomegalovirus Infection in Postrenal Transplant Recipients: 18 Years' Experience From a Tertiary Referral Center |
| Q42872370 | Cytomegalovirus Serostatus Pairing and Deceased Donor Kidney Transplant Outcomes in Adult Recipients With Antiviral Prophylaxis |
| Q43416695 | Cytomegalovirus accelerates chronic allograft nephropathy in a rat renal transplant model with associated provocative chemokine profiles |
| Q38487366 | Cytomegalovirus in the transplanted kidney: a report of two cases and review of prophylaxis. |
| Q36787493 | Cytomegalovirus in transplantation - challenging the status quo. |
| Q40464141 | Cytomegalovirus infection in renal transplant recipients. |
| Q42250541 | Cytomegalovirus infection in renal transplant recipients: one center's experience |
| Q37098580 | Cytomegalovirus infection in renal transplantation: clinical aspects, management and the perspectives. |
| Q37359332 | Cytomegalovirus infections in solid organ transplantation: a review |
| Q44860722 | Cytomegalovirus ischemic colitis of a diabetic renal transplant recipient |
| Q44963388 | Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation |
| Q37778827 | Cytomegalovirus-associated renal allograft rejection: new challenges for antiviral preventive strategies |
| Q45382521 | Cytomegalovirus-specific CD8+ T cells do not develop in all renal transplant patients at risk of virus infection |
| Q37680941 | Defining the risks for cytomegalovirus infection and disease after solid organ transplantation |
| Q59355984 | Development and validation of multiplex real-time PCR assays for rapid detection of cytomegalovirus, Epstein-Barr virus, and polyomavirus BK in whole blood from transplant candidates |
| Q39366092 | Differential Characteristics of Kidney Transplant Recipients According to 1-Year Chronic Kidney Disease Stage 3a and Stage 3b Graft Function |
| Q26863724 | Direct and Indirect Effects of Cytomegalovirus-Induced γδ T Cells after Kidney Transplantation |
| Q37060516 | Disruption of murine cardiac allograft acceptance by latent cytomegalovirus |
| Q40791125 | Early cytomegalovirus-specific T-cell response and estimated glomerular filtration rate identify patients at high risk of infection after renal transplantation. |
| Q91636564 | Efficacy of Ultralow-Dose Valganciclovir Chemoprophylaxis for Cytomegalovirus Infection in ABO-Incompatible Kidney Transplantation Recipients |
| Q36600835 | Etiology and impact of cytomegalovirus disease on solid organ transplant recipients |
| Q38229930 | Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis |
| Q44738359 | Exposure to mycophenolic acid better predicts immunosuppressive efficacy than exposure to calcineurin inhibitors in renal transplant patients. |
| Q39059608 | Factors affecting eGFR 5-year post-deceased donor renal transplant: analysis and predictive model |
| Q84859127 | Ganciclovir transiently attenuates murine cytomegalovirus-associated renal allograft inflammation |
| Q92503320 | HLA-E Polymorphism Determines Susceptibility to BK Virus Nephropathy after Living-Donor Kidney Transplant |
| Q40590036 | Herpesvirus Respiratory Infections in Immunocompromised Patients: Epidemiology, Management, and Outcomes. |
| Q40232106 | High human cytomegalovirus DNAemia early post-transplantation associates with irreversible and progressive loss of renal function - a retrospective study |
| Q38636935 | High-Dose Acyclovir for Cytomegalovirus Prophylaxis in Seropositive Abdominal Transplant Recipients |
| Q26850340 | Human CMV-specific T-cell responses in kidney transplantation; toward changing current risk-stratification paradigm |
| Q52656958 | Human Cytomegalovirus Infection Increases Both Antibody- and Non-Antibody-Dependent Cellular Reactivity by Natural Killer Cells. |
| Q63740474 | Human Vascular Pericytes and Cytomegalovirus Pathobiology |
| Q34873028 | IL-6 induced by Staphylococcus aureus infection prevents the induction of skin allograft acceptance in mice |
| Q37050965 | Immunobiology of human cytomegalovirus: from bench to bedside. |
| Q42366690 | Immunological Prediction of Cytomegalovirus (CMV) Replication Risk in Solid Organ Transplantation Recipients: Approaches for Regulating the Targeted Anti-CMV Prevention Strategies. |
| Q26766471 | Immunological risk assessment: The key to individualized immunosuppression after kidney transplantation |
| Q30453768 | Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies |
| Q37652611 | Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients. |
| Q40267366 | Impact of Everolimus and Low-Dose Cyclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation. |
| Q34077023 | Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes |
| Q44407642 | Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial |
| Q39242719 | Incidence and Risk Factors for Cytomegalovirus Infection in Patients With Kidney Transplantation: A Single-Center Experience |
| Q82346326 | Increased urinary excretion of transforming growth factor-beta(1) in renal transplant recipients during cytomegalovirus infection |
| Q36516318 | Latent cytomegalovirus infection is an independent risk factor for late graft failure in renal transplant recipients |
| Q36200933 | Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation |
| Q38822159 | Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. |
| Q37803335 | Management of cytomegalovirus infection in solid organ transplantation |
| Q63246845 | Mesangial cells, specialized renal pericytes and cytomegalovirus infectivity: Implications for HCMV pathology in the glomerular vascular unit and post-transplant renal disease |
| Q44093109 | Monitoring of CD38high expression in peripheral blood CD8+ lymphocytes in patients after kidney transplantation as a marker of cytomegalovirus infection. |
| Q33347669 | Oral manifestation of cytomegalovirus associated with herpes simplex virus in renal transplant recipient |
| Q98463793 | Organ immune responses - don't forget the structural cells |
| Q47766934 | Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients |
| Q53120860 | Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction. |
| Q36293963 | Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients |
| Q38151922 | Pretransplant identification of acute rejection risk following kidney transplantation |
| Q43653857 | Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation. |
| Q85417735 | Prevalence and clinical impact of cytomegalovirus infection and disease in renal transplantation: ten years of experience in a single center |
| Q37003102 | Prevention of allograft tolerance by bacterial infection with Listeria monocytogenes |
| Q41089597 | Primary Cytomegalovirus Infection Significantly Impacts Circulating T Cells in Kidney Transplant Recipients. |
| Q36262672 | Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients Is Associated with Protracted Cold Ischemic Time of Seropositive Donor Organs |
| Q46618896 | Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients |
| Q40312159 | Reactivation of cytomegalovirus predicts poor prognosis in patients on intensive immunosuppressive treatment for collagen-vascular diseases |
| Q39091657 | Relationship Among Viremia/Viral Infection, Alloimmunity, and Nutritional Parameters in the First Year After Pediatric Kidney Transplantation |
| Q41728131 | Rhabdomyolysis associated with cytomegalovirus infection in kidney transplant recipients |
| Q37754716 | Role of bacterial infections in allograft rejection |
| Q39759053 | Screening for latent BK virus infection in a renal transplant population for the first time in Romania: a single-center experience |
| Q44577592 | Significance of cytomegalovirus infection in renal transplantation. |
| Q45203333 | Sirolimus addition is beneficial for renal allograft dysfunction due to simultaneous acute rejection episode and calcineurin inhibitor nephrotoxicity |
| Q33561715 | Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection |
| Q34455315 | Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation |
| Q37862743 | Surrogate markers of infection: interrogation of the immune system |
| Q33591729 | Surveillance of active human cytomegalovirus infection in hematopoietic stem cell transplantation (HLA sibling identical donor): search for optimal cutoff value by real-time PCR. |
| Q56791527 | Th1/Th2 Cytokine Release Pattern During In Vivo Cytomegalovirus Disease in Solid Organ Transplantation |
| Q38779938 | The Cell Biology of Cytomegalovirus: Implications for Transplantation |
| Q28085440 | The Impact of Infection on Chronic Allograft Dysfunction and Allograft Survival After Solid Organ Transplantation |
| Q37130008 | The effect of cytomegalovirus infection on acute rejection in kidney transplanted patients |
| Q38254037 | The efficacy and cost-effectiveness of valacyclovir in cytomegalovirus prevention in solid organ transplantation |
| Q42248317 | The impact of early cytomegalovirus infection after kidney transplantation on long-term graft and patient survival |
| Q44352400 | The impact of pretransplant cytomegalovirus infection on acute renal allograft rejection |
| Q38193954 | The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients |
| Q46025722 | The influence of cytomegalovirus infections on patient and renal graft outcome: a 3-year, multicenter, observational study (Post-ECTAZ Study). |
| Q63916014 | The use of consensus guidelines for management of cytomegalovirus infection in renal transplantation |
| Q47179318 | Usefulness of valacyclovir prophylaxis for cytomegalovirus infection after anti-thymocyte globulin as rejection therapy. |
| Q46921335 | Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation |
| Q37724248 | Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients. |
| Q41138391 | Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective |
| Q35871893 | Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host |
| Q37097708 | Viral infection after renal transplantation: surveillance and management |
| Q51594265 | Viral infection in renal transplant recipients. |
| Q38240085 | Viral surveillance and subclinical viral infection in pediatric kidney transplantation. |
| Q84028033 | [Indirect effects of cytomegalovirus infection] |
Search more.